Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide

Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Jan 1, 2025: “Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes”.

Intervention

1 paper studies it4 findingsUpdated

PubChemPubChemPubChemChEBIChEBIChEBI

See all 1 papers on acetyl-L-carnitine + alpha-lipoic acid + nicotinamide

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Animals1

What did studies of acetyl-L-carnitine + alpha-lipoic acid + nicotinamide find?

4

Studies of acetyl-L-carnitine + alpha-lipoic acid + nicotinamide measured 4 outcomes, among them hemostatic abnormalities, NAD+ metabolism and HbA1c.

Hemostatic abnormalities

downin rats1

1 study
  1. Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide decreases hemostatic abnormalities in rats (high-calorie diet- and streptozotocin-induced type 2 diabetes) (Partial correction).

    “partially corrected the hemostatic abnormalities.”

    Animalshigh-calorie diet- and streptozotocin-induced type 2 diabetesacetyl-L-carnitine 100 mg/kg; alpha-lipoic acid 50 mg/kg; nicotinamide 100 mg/kg2 weeksmales

    Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes

    Endocrine regulations

NAD+ metabolism

upin rats1

1 study
  1. Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide improves NAD+ metabolism in rats (high-calorie diet- and streptozotocin-induced type 2 diabetes).

    “partially restored the cardiac NAD+ metabolism”

    Animalshigh-calorie diet- and streptozotocin-induced type 2 diabetesheartacetyl-L-carnitine 100 mg/kg; alpha-lipoic acid 50 mg/kg; nicotinamide 100 mg/kg2 weeksmales

    Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes

    Endocrine regulations

More on NAD+ metabolism

HbA1c

downin rats1

1 study
  1. Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide decreases HbA1c in rats (high-calorie diet- and streptozotocin-induced type 2 diabetes) (1.7-fold reduction).

    “Combined treatment lowered the glucose levels by 1.3-fold and HbA1c by 1.7-fold”

    Animalshigh-calorie diet- and streptozotocin-induced type 2 diabetesbloodacetyl-L-carnitine 100 mg/kg; alpha-lipoic acid 50 mg/kg; nicotinamide 100 mg/kg2 weeksmales

    Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes

    Endocrine regulations

More on HbA1c

Fasting blood glucose

downin rats1

1 study
  1. Acetyl-L-carnitine + alpha-lipoic acid + nicotinamide decreases fasting blood glucose in rats (high-calorie diet- and streptozotocin-induced type 2 diabetes) (1.3-fold reduction).

    “Combined treatment lowered the glucose levels by 1.3-fold and HbA1c by 1.7-fold”

    Animalshigh-calorie diet- and streptozotocin-induced type 2 diabetesbloodacetyl-L-carnitine 100 mg/kg; alpha-lipoic acid 50 mg/kg; nicotinamide 100 mg/kg2 weeksmales

    Mitochondria-targeting compounds for management of metabolic and hemostatic abnormalities associated with heart dysfunctions in experimental type 2 diabetes

    Endocrine regulations

More on Fasting blood glucose

Latest